SCHEDULE 13G: BlackRock Discloses 5.4% Stake in Eledon Pharmaceuticals
Schedule 13G Filing
BlackRock, Inc. has reported a 5.4% beneficial ownership stake in Eledon Pharmaceuticals, Inc., holding over 3.25 million shares of common stock.
Summary
- BlackRock, Inc. has filed a Schedule 13G indicating beneficial ownership of Eledon Pharmaceuticals, Inc. common stock.
- BlackRock, Inc. beneficially owns an aggregate of 3,252,910 shares, representing 5.4% of the class.
- Of these shares, BlackRock holds sole voting power over 3,166,867 shares and sole dispositive power over 3,252,910 shares.
- The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Eledon Pharmaceuticals, Inc.
- The event date requiring this filing was June 30, 2025, with the statement filed on July 17, 2025.
- Several BlackRock subsidiaries, including BlackRock Advisors, LLC, BlackRock Fund Advisors, BlackRock Institutional Trust Company, National Association, BlackRock Financial Management, Inc., and BlackRock Investment Management, LLC, are identified as entities that beneficially own 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: Neutral. This is a factual disclosure of an ownership stake, not a performance report or strategic announcement.
Future Outlook
NA
Management Comments
- Securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
Industry Context
NA
Stakeholder Impact
- The disclosure of a significant institutional ownership stake by BlackRock may be viewed positively by other investors, potentially signaling confidence in Eledon Pharmaceuticals, Inc.
Key Dates
| Date | Description |
|---|---|
| 2025-01-21 | Date of Power of Attorney execution by BlackRock, Inc. |
| 2025-06-30 | Date of event which requires the filing of this statement. |
| 2025-07-17 | Date of filing and signature by BlackRock, Inc. |
Keywords
Eledon Pharmaceuticals, BlackRock, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, SEC Filing, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.